Navigation Links
Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced positive results from a three-month open-label extension study of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation (OIC) in patients with advanced illness. The results are scheduled to be presented at the Multinational Association of Supportive Care in Cancer (MASCC) Symposium in St. Gallen, Switzerland.

Eighty-two OIC patients completed a placebo-controlled phase 3 study (MNTX 302), and then participated in the three-month open-label extension study of subcutaneous methylnaltrexone. The goal of the extension study was to obtain efficacy and safety data on subcutaneous methylnaltrexone, administered as needed, for up to three months.

Forty-two OIC patients received subcutaneous methylnaltrexone previously in the double-blind MNTX 302 study, and then entered this open-label extension study. For these forty-two patients, the mean laxation response rates (laxation within four hours) were 45.5% during the first month, 57.7% in the second month, and 57.3% in the third and final month. For the remaining forty patients who had first received placebo in the double-blind MNTX 302 study prior to entering this open-label extension study, laxation response rates were 48.3% during the first month, 47.6% in the second month, and 52.1% in the third and final month. Consistent with previous studies, subcutaneous methylnaltrexone was generally well-tolerated in the three-month open-label study, and the most common adverse event reported was abdominal pain which was typically mild-to-moderate in severity.

"These results show that methylnaltrexone, when administered subcutaneously for up to three months, continued to induce laxation in advanced illness patients with OIC," commented Paul J. Maddon,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:5/23/2013)... 2013  Haemonetics Corporation (NYSE: HAE ) announced ... EVP-Business Development, will present at The Deutsche Bank 38 th ... MA on May 29, 2013 at 1:30pm Eastern ... The public may access Mr. Lindop,s presentation live via ... Haemonetics (NYSE: HAE ) is a ...
(Date:5/23/2013)...  TeamHealth Medical Call Center (THMCC), a premier ... lines, announces its newly formed Clinical Advisory Committee. ... leaders, provides clinical expertise to advance THMCC,s purpose ... hospital clients, physician clients and patients. ... imperative to continuously advance our services and improve ...
(Date:5/23/2013)... ARBOR, Mich. , May 23, 2013  Every day, ... flow of air to his lungs. April and ... the dire predictions weren,t true. "Quite a few ... the hospital alive," says April Gionfriddo , ... were desperate. Anything that would work, we would take it ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... Novavax, Inc. (Nasdaq: NVAX) a clinical-stage ... results from its 2009 H1N1 virus-like particle (VLP) pandemic ... 7th World Health Organization Meeting (WHO) on Evaluation of ... held at the WHO headquarters in Geneva, Switzerland where ...
... Technologies Corporation (Nasdaq: LIFE ), today ... winners of the European Ion Torrent Personal Genome Machine ... http://photos.prnewswire.com/prnh/20110216/MM49339LOGO ) Each scientist will receive an Ion ... Torrent sequencing technology, these scientists will be able to give ...
Cached Medicine Technology:NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 2NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 3NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 4NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 5Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 2Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 3Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 4Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 5
(Date:5/23/2013)... Mayo Clinic researchers have used next generation genomic analysis ... cancer tumors have similar genetic origins, which may help ... in the journal Cancer Research . , "This ... next generation sequencing in adjacent Gleason patterns in the ... in pathology," says ,John Cheville, M.D., Mayo Clinic pathologist ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... Click here to read the full ... increasingly seeing their success develop through merger and ... according to new research carried out by MaRS , ... has compiled its research into a series of articles ... research have shown the general trend that the success ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul McCartney will ... North America. This well known ticket website has slashed ... help McCartney fans see Sir Paul live in concert. ... is also offering the customer appreciation code SAVE for additional ... she is also a huge McCartney fan and plans to ...
(Date:5/23/2013)... (HealthDay News) -- Symptoms of borderline personality disorder ... diagnosis and treatment. But researchers in Canada say ... unique to borderline personality disorder: a tendency to ... "They have difficulty processing facial emotions and will ... said Anthony Ruocco, a clinical neuropsychologist and assistant ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3
... New Non-Steroidal Skin Treatment to Treat All ... with Steroids, BARRINGTON, Ill., Oct. 19 Steroids have ... abuse. There must be reasons why,people use steroid products on ... largest organ of the human body, and it needs to ...
... 19 Uroplasty, Inc. (Amex:,UPI) announced today that ... Securities and Exchange Commission in anticipation of a ... of its,common stock. Craig-Hallum Capital Group and ... connection with this proposed public offering.,A copy of ...
... Scans, Oct 26 & 27, as Part of Clinical Study., CHICAGO, ... Stage III or Stage IV ... at no charge as part of a clinical trial. ... cancer that tests positive for a protein called human ...
... Holdings, Inc. and its,operating subsidiary, US Oncology, Inc., ... November 8, 2007. A conference call and ... EST, for the company,s bondholders following the distribution ... US Oncology,s management,team will discuss the financial results. ...
... Oct. 18 West Pharmaceutical,Services, Inc. (NYSE: ... announcement that it has decided to discontinue marketing ... to the,Company,s customer, Nektar Therapeutics, Inc. The Company,s ... the Exubera inhalation device for Nektar. "We ...
... cancer patients with the poorest prognosis -- those with a ... may survive longer with a drug that chokes off ... by researchers at Dukes Preston Robert Tisch Brain Tumor Center, ... and a standard chemotherapy agent, may increase the amount of ...
Cached Medicine News:Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Brain Screenings Offered to Breast Cancer Patients During Breast Cancer Awareness Month 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:Drug combination might offer hope for patients deadly brain tumors 2
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin XL Magnum Cup Curettes, extra long (XL) curettes, black handles, lightweight, length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Caspar Curette, 250 mm, 10"....
Medicine Products: